You are here:
Decapeptyl SR 11.25 mg (Triptorelin acetate®)
Advice
Following an abbreviated submission
Decapeptyl™ SR 11.25mg is accepted for use within NHS Scotland for the treatment of advanced prostate cancer in patients for whom the use of triptorelin is appropriate and who would benefit from reduced frequency of administration compared with Decapeptyl™ SR 3mg (every 3 months vs every 28 days).
Drug Details
| Drug Name: | Decapeptyl SR 11.25 mg (Triptorelin acetate®) |
|---|---|
| SMC Drug ID: | 109/04 |
| Manufacturer: | Ipsen Ltd |
| Indication: | Advanced Prostate Cancer |
| BNF Category: | |
| Sub Category: | 8.3 Sex hormones and hormone antagonists in malignant disease |
| Submission Type: | Abbreviated Submission |
| Status: | Accepted |
| Date Advice Published: | 12 July 2004 |